Chris Car­pen­ter joins the R&D ex­o­dus out of phar­ma; George Church's eGe­n­e­sis se­lects Jodie Mor­ri­son as new CEO

⇨ Af­ter spend­ing the last decade in Big Phar­ma R&D, Chris Car­pen­ter is mak­ing the leap to biotech, join­ing the ris­ing star Ru­bius as chief med­ical of­fi­cer. Car­pen­ter — a for­mer as­so­ciate pro­fes­sor at Har­vard Med, where he ran a lab for years — spent the last six years at GSK, where he wrapped up his stint as a se­nior VP and head of can­cer epi­ge­net­ics. He jumped from Har­vard to Mer­ck to GSK, where he was cred­it­ed with lead­ing the de­vel­op­ment of Votri­ent. And at Mer­ck he worked on MK-4827, which went on to be­come Tesaro’s PARP drug Ze­ju­la. He’s go­ing to one of the best fi­nanced up­starts in biotech. Just a few months ago, Cam­bridge, MA-based Ru­bius lined up a $120 mil­lion round, with plans to de­vel­op a full pipeline of new drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.